Malmö 29 December 2022 **PRESS RELEASE**

First cohort dosed in Aptahem's FIH study

Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, announces today that the first cohort of healthy volunteers (HV) have been dosed in the clinical First in Human (FIH) study.

The first HV subjects have now successfully been dosed and the first cohort is completed in the randomized, placebo-controlled Phase 1 study evaluating the safety and tolerability of intravenous Apta-1. After the follow-up visits of this first cohort, Apta-1 seems safe and well tolerated.

Clinical Research Director Suzanne Kilany comments:
"It is with great pleasure that we receive the news that the first cohort of the dosed HV went well. This was not unexpected as we have seen similar results in the non-clinical studies with Apta-1. However, first in human dosing is always exciting, as there are no guarantees that the previous results can be achieved in human. We will now proceed with the next dose cohorts after the holiday seasons and we hope to see the same promising results in also the following cohorts."

For further information:
Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
E-mail: ml@aptahem.com

About Aptahem
Aptahem AB (APTA) is a clinical stage biotechnology company that develops aptamer-based pharmaceuticals for the treatment of acute, life-threatening conditions in which a combination of coagulation, inflammation and tissue damage are involved. The company's lead candidate, Apta-1, is currently in early clinical phase. Apta-1 has in preclinical studies, by its anti-thrombotic, immunomodulating and tissue repairing characteristics, shown very positive and promising results as treatment for sepsis and critical conditions associated with sepsis. For more information, please visit www.aptahem.com